SEC Form 4 · accession 0001193125-26-283141
Kymera Therapeutics, Inc. · KYMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce Booth
Director
Period of report
Jun 24, 2026
Accepted (ET)
Jun 25, 2026 · 6:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001815442
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $99.87 | Jun 24, 2026 | A | 6,068 | A | — | Jun 23, 2036 | Common Stock | 6,068 | 6,068 | D |
Explanation of responses
- F1The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.
- F2This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.